Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDX NYSE:EBS NYSE:JNJ NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$26.77-2.8%$24.01$14.40▼$31.66$1.83B1.331.09 million shs1.21 million shsEBSEmergent Biosolutions$9.08-9.6%$8.45$4.02▼$12.73$535.65M2.04971,490 shs1.17 million shsJNJJohnson & Johnson$190.66-0.2%$178.48$140.68▼$192.10$460.19B0.48.86 million shs9.46 million shsMNKDMannKind$4.88-5.1%$4.81$3.38▼$7.63$1.58B1.084.22 million shs8.95 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-2.80%+1.36%+7.25%+16.85%-11.03%EBSEmergent Biosolutions-9.42%-0.48%+13.96%+23.65%+1.52%JNJJohnson & Johnson-0.16%+1.14%+8.51%+21.54%+18.66%MNKDMannKind-5.12%-15.33%-12.44%+29.36%-24.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$26.77-2.8%$24.01$14.40▼$31.66$1.83B1.331.09 million shs1.21 million shsEBSEmergent Biosolutions$9.08-9.6%$8.45$4.02▼$12.73$535.65M2.04971,490 shs1.17 million shsJNJJohnson & Johnson$190.66-0.2%$178.48$140.68▼$192.10$460.19B0.48.86 million shs9.46 million shsMNKDMannKind$4.88-5.1%$4.81$3.38▼$7.63$1.58B1.084.22 million shs8.95 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-2.80%+1.36%+7.25%+16.85%-11.03%EBSEmergent Biosolutions-9.42%-0.48%+13.96%+23.65%+1.52%JNJJohnson & Johnson-0.16%+1.14%+8.51%+21.54%+18.66%MNKDMannKind-5.12%-15.33%-12.44%+29.36%-24.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.67Moderate Buy$46.1372.30% UpsideEBSEmergent Biosolutions 2.33Hold$13.5048.74% UpsideJNJJohnson & Johnson 2.73Moderate Buy$192.941.20% UpsideMNKDMannKind 2.89Moderate Buy$10.86122.62% UpsideCurrent Analyst Ratings BreakdownLatest EBS, JNJ, MNKD, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$209.0010/10/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$176.00 ➝ $178.0010/10/2025MNKDMannKindLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.0010/9/2025JNJJohnson & JohnsonThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$186.00 ➝ $212.0010/8/2025CLDXCelldex TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025EBSEmergent BiosolutionsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025JNJJohnson & JohnsonWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)10/8/2025MNKDMannKindWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/7/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$200.00 ➝ $213.0010/6/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$172.00 ➝ $193.0010/6/2025MNKDMannKindZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M253.25N/AN/A$11.26 per share2.38EBSEmergent Biosolutions$1.04B0.46$1.74 per share5.23$8.91 per share1.02JNJJohnson & Johnson$88.82B5.17$13.09 per share14.56$29.69 per share6.42MNKDMannKind$285.50M5.24$0.13 per share37.04($0.29) per share-16.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)EBSEmergent Biosolutions-$190.60M$2.453.704.38N/A16.38%24.63%8.97%10/29/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3520.3917.222.4025.00%32.49%13.00%10/14/2025 (Estimated)MNKDMannKind$27.59M$0.1144.3421.20N/A10.87%-32.60%7.81%11/6/2025 (Estimated)Latest EBS, JNJ, MNKD, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025MNKDMannKind$0.01N/AN/AN/A$80.47 millionN/A11/5/2025Q3 2025CLDXCelldex Therapeutics-$0.88N/AN/AN/A$1.12 millionN/A10/29/2025Q3 2025EBSEmergent Biosolutions-$0.01N/AN/AN/A$203.67 millionN/A10/14/2025Q3 2025JNJJohnson & Johnson$2.78N/AN/AN/A$23.73 billionN/A8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/6/2025Q2 2025EBSEmergent Biosolutions-$0.26$0.16+$0.42-$0.22$148.55 million$140.90 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.73%N/A55.61%64 YearsMNKDMannKindN/AN/AN/AN/AN/ALatest EBS, JNJ, MNKD, and CLDX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A19.6719.67EBSEmergent Biosolutions1.255.663.00JNJJohnson & Johnson0.501.010.76MNKDMannKindN/A2.502.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AEBSEmergent Biosolutions78.40%JNJJohnson & Johnson69.55%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%EBSEmergent Biosolutions1.20%JNJJohnson & Johnson0.16%MNKDMannKind2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableEBSEmergent Biosolutions2,42053.35 million52.71 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableMNKDMannKind400306.83 million298.54 millionOptionableEBS, JNJ, MNKD, and CLDX HeadlinesRecent News About These CompaniesMannKind (NASDAQ:MNKD) Coverage Initiated at Leerink Partners5 hours ago | marketbeat.comMannKind (NASDAQ:MNKD) Shares Down 5.6% - Time to Sell?October 10 at 8:44 PM | marketbeat.comMannKind (NASDAQ:MNKD) Given "Hold (C)" Rating at Weiss RatingsOctober 10 at 7:51 AM | marketbeat.comMannKind Completes Acquisition of scPharmaOctober 9 at 6:11 PM | tipranks.comMannKind (NASDAQ:MNKD) Upgraded at Zacks ResearchOctober 8 at 7:53 AM | marketbeat.comMannKind Corporation Completes Acquisition of scPharmaceuticals Inc. to Enhance Revenue Growth and Expand Cardiometabolic Therapy PortfolioOctober 7, 2025 | quiverquant.comQMannKind Corporation Completes Acquisition of scPharmaceuticals Inc. to Enhance Growth in Cardiometabolic CareOctober 7, 2025 | quiverquant.comQMannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic CareOctober 7, 2025 | globenewswire.comMannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic CareOctober 7, 2025 | globenewswire.comMannKind Corporation (NASDAQ:MNKD) Given Average Rating of "Buy" by AnalystsOctober 2, 2025 | marketbeat.comBuy Rating for MannKind Supported by Strong Tyvaso Efficacy in IPF TreatmentOctober 1, 2025 | tipranks.comMannKind Corporation Appoints Dr. Ajay Ahuja as Chief Medical OfficerSeptember 29, 2025 | quiverquant.comQMannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical OfficerSeptember 29, 2025 | globenewswire.comMannKind (NASDAQ:MNKD) Shares Down 5% - Time to Sell?September 23, 2025 | marketbeat.comVoya Investment Management LLC Sells 58,689 Shares of MannKind Corporation $MNKDSeptember 22, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Receives "Buy" Rating from HC WainwrightSeptember 19, 2025 | marketbeat.comStuart Tross Sells 47,000 Shares of MannKind (NASDAQ:MNKD) StockSeptember 18, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Short Interest Down 23.9% in AugustSeptember 18, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Insider Stuart Tross Sells 47,000 SharesSeptember 18, 2025 | insidertrades.comMannKind (NASDAQ:MNKD) Stock Price Down 4.2% - Time to Sell?September 16, 2025 | marketbeat.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHSeptember 16, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 20253 Dividend Stocks to Hold Through Market Volatility This FallBy Chris Markoch | September 16, 20253 Small-Cap Stocks to Watch After the Fed’s Rate CutsBy Chris Markoch | September 24, 2025Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma GiantsBy Gabriel Osorio-Mazilli | October 6, 2025Why AbbVie and Johnson & Johnson Could Outperform PfizerBy Chris Markoch | October 8, 2025EBS, JNJ, MNKD, and CLDX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$26.77 -0.77 (-2.80%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$26.34 -0.43 (-1.61%) As of 10/10/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Emergent Biosolutions NYSE:EBS$9.08 -0.96 (-9.60%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$9.07 0.00 (-0.02%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Johnson & Johnson NYSE:JNJ$190.66 -0.43 (-0.22%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$191.05 +0.40 (+0.21%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.MannKind NASDAQ:MNKD$4.88 -0.26 (-5.12%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$4.82 -0.06 (-1.19%) As of 10/10/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
